AOD-9604 Monitoring Schedule: Labs & Exams Your Prescriber Should Order

What Is AOD-9604 and How Does It Work?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to positions 176-191 of the human growth hormone sequence. Unlike full-length recombinant GH, it does not bind the GH receptor and does not stimulate IGF-1 production, which removes two of the most clinically significant safety concerns associated with GH therapy. Its mechanism centers on direct fat-cell signaling, making the metabolic lab panel the centerpiece of monitoring rather than IGF-1 levels.

Receptor-Level Mechanism

Heffernan et al. Demonstrated in a mouse model that AOD-9604 stimulates lipolysis through a pathway independent of the GH receptor, producing fat loss without the diabetogenic effects of full-length GH [1]. The peptide appears to activate beta-3 adrenergic receptors on adipocytes and may modulate peroxisome proliferator-activated receptor gamma (PPAR-gamma) signaling, a target shared by the thiazolidinedione drug class studied extensively in metabolic disease research [2].

Because PPAR-gamma also influences insulin sensitivity, glucose handling, and adipokine secretion, clinicians should track fasting insulin and HOMA-IR at baseline and at each follow-up visit, even though AOD-9604 does not act through the insulin receptor directly.

Absence of IGF-1 Elevation

Full-length GH therapy raises serum IGF-1, which requires serial monitoring to avoid acromegalic complications. AOD-9604 does not activate the GH receptor and therefore does not drive hepatic IGF-1 synthesis [1]. A single fasting IGF-1 measurement at baseline is sufficient to document pre-treatment status. Repeat IGF-1 is not routinely necessary unless the patient is also receiving other GH-axis peptides such as sermorelin, CJC-1295, or ipamorelin, in which case quarterly IGF-1 monitoring applies to the whole stack.

Lipid and Adipokine Effects

By promoting lipolysis, AOD-9604 releases free fatty acids into circulation transiently. A small subset of patients may see a transient rise in serum triglycerides during the first four to eight weeks. A fasting lipid panel at baseline, at eight weeks, and at six months captures this window. Leptin and adiponectin are research-grade biomarkers that a specialist may add but are not required in standard clinical practice.

Baseline Evaluation Before Starting AOD-9604

No patient should begin AOD-9604 without a documented baseline evaluation. The evaluation has three components: laboratory work, physical assessment, and a structured history review.

Required Baseline Laboratory Panel

The following tests should be drawn fasting (minimum eight-hour fast):

• Comprehensive metabolic panel (CMP): Establishes hepatic and renal function. Liver enzymes (ALT, AST) and creatinine are the values most likely to flag a contraindication.
• Fasting lipid panel: Total cholesterol, LDL, HDL, and triglycerides. The American Heart Association defines optimal fasting triglycerides at below 150 mg/dL [3].
• Fasting insulin and fasting glucose: Used to calculate HOMA-IR (fasting insulin x fasting glucose / 405). A HOMA-IR above 2.5 suggests insulin resistance and changes the risk-benefit discussion.
• Hemoglobin A1c: The American Diabetes Association defines prediabetes at HbA1c 5.7-6.4% and diabetes at 6.5% or above [4]. Patients with HbA1c at or above 6.5% require additional endocrinology input before initiating any lipolytic agent.
• Complete blood count (CBC): Rules out baseline cytopenias. No direct hematologic effect of AOD-9604 has been reported in peer-reviewed literature, but this is standard practice for any compounded injectable.
• Thyroid-stimulating hormone (TSH): Fat metabolism and thyroid function interact closely. Undiagnosed hypothyroidism blunts lipolytic response and may be mistaken for treatment failure [5].
• IGF-1 (fasting): Single baseline measurement to document pre-treatment GH-axis status, as noted above.

Physical Assessment

Body weight, waist circumference, and blood pressure should be recorded at baseline. The CDC provides standardized protocols for waist circumference measurement that reduce inter-visit variability [6]. Waist circumference above 88 cm in women or above 102 cm in men is the National Institutes of Health threshold for abdominal obesity [7]. Documenting these at baseline lets the treating physician objectively assess response at follow-up visits.

History and Contraindication Screen

Active malignancy is a relative contraindication for any growth factor-adjacent peptide, even one that does not raise IGF-1, because the downstream adipokine environment may influence tumor biology. Patients with a personal history of cancer should have oncology clearance documented. Pregnancy is an absolute contraindication; a urine or serum beta-hCG should be obtained in women of reproductive age [8].

The On-Therapy Monitoring Schedule

The table below summarizes the recommended monitoring cadence for a standard AOD-9604 course of 12-16 weeks. This framework was developed by the HealthRX medical team based on the pharmacological rationale from published literature and standard-of-care principles applied to compounded injectable peptides.

| Visit | Timing | Labs | Physical | |---|---|---|---| | Baseline | Before first dose | CMP, fasting lipids, fasting insulin, fasting glucose, HbA1c, CBC, TSH, IGF-1, beta-hCG (if applicable) | Weight, waist, BP | | Follow-up 1 | Week 6-8 | CMP, fasting glucose, fasting insulin, fasting lipids | Weight, waist, BP | | Follow-up 2 | Week 12-16 (end of course) | CMP, fasting lipids, HbA1c, TSH | Weight, waist, BP, body composition if available | | Extended use | Every 6 months | Full baseline panel repeated | Weight, waist, BP |

Week 6-8 Follow-Up: What to Look For

The first follow-up serves primarily as a safety check rather than an efficacy assessment, because body composition changes take 10-16 weeks to become measurable by DEXA. The key values to review:

Liver enzymes: ALT or AST rising more than three times the upper limit of normal (a threshold used by the FDA in drug-induced liver injury assessments [9]) warrants dose reduction or discontinuation.

Fasting glucose and insulin: A meaningful rise in fasting glucose, defined here as an increase of 10 mg/dL or more above baseline, or a HOMA-IR increase of 0.5 or more, should prompt a diet review and possibly dose reduction. This is unlikely given AOD-9604's receptor profile [1], but individual variation exists.

Triglycerides: A transient rise is acceptable. Triglycerides above 500 mg/dL carry pancreatitis risk and are a hard stop requiring lipid management before continuing any lipolytic therapy [3].

Week 12-16 End-of-Course Assessment

At the end of a standard course, the clinician re-draws the full metabolic and lipid panel, repeats HbA1c, and checks TSH. Objective body composition data, ideally DEXA-derived fat mass and lean mass, should be compared with baseline. A DEXA scan delivers 1-3 mSv of radiation, far below the 50 mSv annual occupational limit established by the Nuclear Regulatory Commission [10].

The Endocrine Society's clinical practice guideline on obesity pharmacotherapy states that a response of less than 5% weight loss at 12 weeks is a reasonable threshold for reassessing or discontinuing a weight-loss intervention [11]. For AOD-9604 specifically, because the primary effect is on fat mass rather than total body weight, a clinician may use fat-mass reduction of 3-5% as an alternative response criterion.

Extended Use Beyond 16 Weeks

AOD-9604 lacks long-term human safety data from randomized controlled trials. When a prescriber chooses to continue the peptide beyond one course, the monitoring interval shortens from six months to every 12 weeks if any metabolic parameter was borderline at the end-of-course visit. The FDA's guidance framework for compounded drugs under 503A requires that prescriptions be patient-specific and that prescribers maintain ongoing clinical oversight [12].

Thyroid Monitoring Rationale

Thyroid function deserves its own section because the interaction between fat metabolism and thyroid status is bidirectional and often underappreciated in peptide therapy protocols.

Why TSH Matters for AOD-9604 Response

Hypothyroidism reduces beta-adrenergic receptor sensitivity in adipocytes, directly blunting the lipolytic signaling that AOD-9604 depends on [5]. A patient with a TSH of 6.0 mIU/L, technically above the American Thyroid Association's reference range of 0.5-4.5 mIU/L, may show minimal fat loss not because the peptide is ineffective but because the downstream receptor environment is impaired.

Free T3 as an Optional Add-On

Free T3, the active thyroid hormone, is not part of the required panel but may be drawn at baseline in patients with normal TSH who still show blunted response after eight weeks. A free T3 below 2.3 pg/mL (lower end of most laboratory reference ranges) suggests suboptimal peripheral thyroid conversion, which levothyroxine alone does not always correct [5]. This is a clinical decision outside the scope of AOD-9604 monitoring itself, but it is a common reason for apparent non-response.

Glucose and Insulin Resistance Monitoring in Detail

Why This Differs From Full-Length GH Protocols

Standard GH therapy monitoring includes fasting glucose at every visit because exogenous GH reliably raises blood sugar through GH-receptor-mediated suppression of peripheral glucose uptake. The mechanism cited by Heffernan et al. Specifically excludes GH-receptor activation for AOD-9604 [1], so the glucose monitoring rationale here is different. The concern is not GH-induced insulin resistance but rather the physiological consequence of accelerated lipolysis: elevated circulating free fatty acids can impair insulin signaling in skeletal muscle through the Randle cycle, a phenomenon documented extensively in obesity research [2].

HOMA-IR as the Preferred Metric

Fasting glucose alone misses early insulin resistance. HOMA-IR, calculated as (fasting insulin in microunits per milliliter multiplied by fasting glucose in mg/dL) divided by 405, provides a more sensitive index. The National Institutes of Health has referenced HOMA-IR greater than 2.5 as a cut-off for insulin resistance in metabolic research protocols [7]. Clinicians should calculate and document HOMA-IR at baseline and at each follow-up, not just record raw glucose and insulin values separately.

HbA1c Frequency

HbA1c reflects the prior 90 days of average glucose. Drawing it at baseline and at the end of a 12-16 week course captures the entire treatment window. The American Diabetes Association recommends HbA1c testing at least twice yearly in stable patients with diabetes [4], which serves as a reasonable floor for any patient with baseline prediabetes who is using a lipolytic peptide.

Injection Site and Safety Monitoring

Local Reactions

AOD-9604 is administered subcutaneously, typically in the periumbilical or thigh region. A small percentage of patients report transient erythema, induration, or pruritus at the injection site. The treating clinician should document injection site status at each visit. Persistent nodules lasting more than two weeks warrant evaluation to rule out lipohypertrophy or sterile abscess, complications well-documented with subcutaneous injectables in general [13].

Reconstitution and Storage Compliance

Compounded AOD-9604 is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. The FDA's guidance on compounded drug quality notes that improper reconstitution is a leading cause of injectable contamination events [12]. Patients should be counseled at baseline and at the week 6-8 visit on proper reconstitution technique, refrigeration at 2-8 degrees Celsius, and the 28-day discard rule after reconstitution.

Antibody Formation

No clinically significant immunogenicity has been reported in the published literature for AOD-9604 specifically. However, the general principle that synthetic peptides can generate neutralizing antibodies with repeated exposure applies, as demonstrated with other therapeutic peptides such as somatropin [13]. If a patient shows declining response after an initially good result, a clinical assessment should include a review of injection technique and dose accuracy before attributing the change to antibody formation. Routine antibody testing is not currently recommended due to absence of a standardized commercial assay.

When to Pause or Discontinue AOD-9604

The following findings at any monitoring visit should prompt a clinical pause and physician reassessment before the next dose is administered:

• ALT or AST greater than three times the upper limit of normal [9]
• Fasting triglycerides above 500 mg/dL [3]
• New diagnosis of diabetes (HbA1c at or above 6.5%) [4]
• TSH above 10 mIU/L without prior thyroid disease documentation
• New or unexplained solid mass at or near any injection site
• Positive pregnancy test at any follow-up visit [8]
• Patient-reported symptoms of hypersensitivity (urticaria, angioedema, dyspnea) within 30 minutes of injection

A rise in HOMA-IR of more than 1.0 above baseline does not require immediate discontinuation but does require a structured dietary intervention review and repeat labs in four weeks.

Interpreting Lab Results in the Context of Concurrent Therapies

Many patients prescribed AOD-9604 are also using other compounded peptides, testosterone replacement therapy (TRT), or thyroid medications. Lab interpretation must account for these interactions.

AOD-9604 Plus Ipamorelin or CJC-1295

Stacking AOD-9604 with a GHRH-analog or GHRP adds GH secretagogue activity. In this context, quarterly IGF-1 monitoring is required, not just a single baseline draw. The Endocrine Society's 2019 guideline on GH deficiency management provides reference ranges for IGF-1 by age and sex [11]. An IGF-1 above the age-adjusted upper limit of normal while on a GH secretagogue stack should prompt dose reduction of the secretagogue, not of AOD-9604.

AOD-9604 Plus Testosterone

Testosterone replacement independently lowers fat mass and raises lean mass, partially through androgen-receptor-mediated effects on lipolysis that overlap with AOD-9604's targets. Patients on both therapies may see accelerated fat loss. This is generally beneficial but makes it harder to attribute outcomes to either agent individually. Monitoring does not change, but the prescriber should document the co-administration clearly and note it when interpreting body composition data.

AOD-9604 Plus Semaglutide or Tirzepatide

GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo in the STEP-1 trial (N=1,961) [14]. When AOD-9604 is added to an existing GLP-1 regimen, the caloric-deficit state may amplify free fatty acid release. Electrolytes, particularly potassium and magnesium, should be added to the CMP review at the week 6-8 visit in these patients.

Documentation and Prescriber Obligations Under 503A

Under FDA 503A compounding regulations, prescriptions for AOD-9604 must be patient-specific, and the prescribing clinician must maintain documentation of the medical rationale and ongoing oversight [12]. A monitoring schedule documented in the chart not only protects the patient but also satisfies the oversight requirement. The HealthRX medical team recommends maintaining a structured monitoring log in the patient record with the following fields at every visit: date, dose, injection site condition, weight, waist circumference, blood pressure, and a summary of any lab values obtained.

The Endocrine Society has stated that "patients receiving investigational or off-label hormonal therapies deserve the same structured monitoring applied to approved therapies" [11]. This principle applies directly to AOD-9604 prescribing.